Cim LLC Grows Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Cim LLC lifted its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 7.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,016 shares of the company’s stock after acquiring an additional 701 shares during the quarter. Cim LLC’s holdings in Amphastar Pharmaceuticals were worth $401,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. YHB Investment Advisors Inc. purchased a new position in Amphastar Pharmaceuticals during the 1st quarter worth $27,000. Innealta Capital LLC purchased a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at $55,000. Blue Trust Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after acquiring an additional 309 shares in the last quarter. nVerses Capital LLC lifted its stake in Amphastar Pharmaceuticals by 37.5% in the second quarter. nVerses Capital LLC now owns 2,200 shares of the company’s stock worth $88,000 after acquiring an additional 600 shares during the period. Finally, 1620 Investment Advisors Inc. bought a new position in Amphastar Pharmaceuticals during the 2nd quarter worth about $93,000. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

NASDAQ AMPH opened at $48.35 on Wednesday. The firm’s fifty day simple moving average is $45.55 and its two-hundred day simple moving average is $42.75. The firm has a market capitalization of $2.36 billion, a P/E ratio of 16.73, a P/E/G ratio of 0.92 and a beta of 0.82. The company has a current ratio of 3.52, a quick ratio of 2.63 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The firm had revenue of $182.39 million for the quarter, compared to the consensus estimate of $171.29 million. Analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.71 EPS for the current fiscal year.

Insider Activity

In other news, EVP Rong Zhou sold 4,000 shares of Amphastar Pharmaceuticals stock in a transaction on Monday, August 26th. The shares were sold at an average price of $48.35, for a total transaction of $193,400.00. Following the completion of the sale, the executive vice president now directly owns 118,388 shares in the company, valued at $5,724,059.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, EVP Rong Zhou sold 4,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the transaction, the executive vice president now directly owns 118,388 shares in the company, valued at $5,724,059.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the completion of the sale, the director now owns 75,409 shares in the company, valued at approximately $3,504,256.23. The disclosure for this sale can be found here. Insiders have sold a total of 34,383 shares of company stock worth $1,524,123 over the last 90 days. 27.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

AMPH has been the subject of several recent research reports. Piper Sandler reduced their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. StockNews.com upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, September 20th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $63.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.